var data={"title":"Potassium chloride: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium chloride: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6813?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-chloride-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium chloride: Patient drug information&quot;</a> and <a href=\"topic.htm?path=potassium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium chloride: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211820\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>K-Sol [DSC];</li>\n      <li>K-Tab;</li>\n      <li>Klor-Con;</li>\n      <li>Klor-Con 10;</li>\n      <li>Klor-Con M10;</li>\n      <li>Klor-Con M15;</li>\n      <li>Klor-Con M20;</li>\n      <li>Klor-Con Sprinkle;</li>\n      <li>Micro-K</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211821\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>K-10;</li>\n      <li>K-Dur;</li>\n      <li>Micro-K Extencaps;</li>\n      <li>Roychlor;</li>\n      <li>Slo-Pot;</li>\n      <li>Slow-K</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211838\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Electrolyte Supplement, Oral;</li>\n      <li>\n        Electrolyte Supplement, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211823\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> When maintaining normal daily requirements, IV doses should be incorporated into the patient's maintenance IV fluids. Intermittent IV potassium administration should be reserved for more severe depletion situations in patients undergoing ECG monitoring. Doses expressed as mEq of potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Normal daily requirements:</b> <i>Oral, IV:</i> 40 to 80 mEq/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of hypokalemia:</b> <i>Oral:</i> 20 to 40 mEq/day in 1 to 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of hypokalemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate hypokalemia: <b>Note:</b> If deficits are severe or ongoing losses are great, IV route should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Capsules, tablets, oral solution: Usual dose: 40 to 100 mEq daily in divided doses; limit single doses to 20 to 25 mEq/dose to avoid GI discomfort.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Powder for oral solution (Klor-Con): Usual dose: 40 to 100 mEq daily in 2 to 5 divided doses; limit single doses to 40 mEq/dose; maximum: 200 mEq/24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Some clinicians initiate treatment with 10 to 20 mEq given 2 to 4 times per day (20 to 80 mEq/day), depending upon the severity of the hypokalemia. Total daily doses up to 120 mEq may be necessary as determined by laboratory assessment, patient symptoms and/or ongoing losses (Brophy 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe hypokalemia: Some clinicians initiate treatment with 40 mEq given 3 to 4 times per day; may also administer 20 mEq every 2 to 3 hours in conjunction with IV potassium administration with careful monitoring. Administration of dose &gt;40 mEq orally per dose are typically not well tolerated, resulting in GI irritation and nausea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV intermittent infusion:</i> Peripheral or central line: &le;10 mEq/hour; repeat as needed based on frequently obtained lab values; central line infusion and continuous ECG monitoring highly recommended for infusions &gt;10 mEq/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Potassium dosage/rate of infusion general guidelines (per product labeling): <b>Note:</b> High variability exists in dosing/infusion rate recommendations; therapy guided by patient condition and specific institutional guidelines. As an estimate, 10 mEq of potassium chloride will roughly increase serum levels by 0.1 mEq/L. Patients with more severe forms of hypokalemia (eg, serum potassium levels &lt;3.5 mEq/L) may require increased amounts due to total body potassium deficit (Flurie 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum potassium &gt;2.5 to 3.5 mEq/L: Maximum infusion rate: 10 mEq/hour; maximum concentration: 40 mEq/L; maximum 24-hour dose: 200 mEq</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum potassium &lt;2.5 mEq/L or symptomatic hypokalemia (excluding emergency treatment of cardiac arrest): Maximum infusion rate (central line only): 40 mEq/hour in presence of continuous ECG monitoring and frequent lab monitoring; in selected situations, patients may require up to 400 mEq/24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211833\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=potassium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium chloride: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Maintenance potassium IV doses should be incorporated into the patient's maintenance IV fluids; intermittent IV potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent IV doses &gt;0.5 mEq/kg/<b>hour. </b>Oral solutions are available in two concentrations: 20 mEq/15 mL (1.33 mEq/mL) and 40 mEq/15 mL (2.67 mEq/mL); use extra precaution; verify product formulation for dosage calculation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypokalemia, prevention for ongoing drug losses (eg, concurrent diuretic therapy)</b>: Limited data available: Infants, Children, and Adolescents: Oral: 1 to 2 mEq/kg/day in 1 to 2 divided doses; usual single dose should not exceed usual adult single dose: 20 mEq/dose; although some patients may require a single dose up to 40 mEq/dose (Moffett 2011); some patients may require higher individual daily doses based on lab values and ongoing losses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypokalemia, treatment; mild to moderate</b>: Limited data available: Infants, Children, and Adolescents: Oral: 2 to 5 mEq/kg/day in divided doses; not to exceed 1 to 2 mEq/kg as a single dose or 20 mEq (whichever is less) (Corkins 2015; Moffett 2011); if deficits are severe or ongoing losses are great, IV potassium route should be considered as preferred route of administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypokalemia, treatment; severe</b>: Infants, Children, and Adolescents: Intermittent IV infusion: 0.5 to 1 mEq/kg/dose; maximum dose: 40 mEq/dose; infuse at a rate &le;0.5 mEq/kg/<b>hour</b> (Corkins 2015; Fuhrman 2017; Kliegman 2016); serum concentrations should be evaluated 1 to 2 hours after completion of infusion; may repeat as needed based on lab values; severe depletion or ongoing losses may require &gt;200% of normal daily maintenance (Knudson 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211824\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution, starting at the low end of the dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448467\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling. Reduce initial dose by at least 50% in patients with renal impairment (Kraft 2005). Contraindicated in patients with renal failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448468\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; use oral formulations with caution in patients with cirrhosis and start at the low end of dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211804\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con Sprinkle: 8 mEq [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con Sprinkle: 10 mEq [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Micro-K: 8 mEq, 10 mEq</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mEq, 10 mEq</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con: 20 mEq (1 ea, 30 ea, 100 ea) [contains fd&amp;c yellow #6 (sunset yellow); orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con: 20 mEq (1 ea [DSC], 30 ea [DSC], 100 ea [DSC]); 25 mEq (30 ea [DSC], 100 ea [DSC]) [sugar free; contains fd&amp;c yellow #6 (sunset yellow); fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mEq (1 ea, 30 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mEq (1000 mL); 40 mEq (1000 mL); 0.4 mEq/mL (50 mL); 10 mEq/100 mL (100 mL); 10 mEq/50 mL (50 mL); 20 mEq/100 mL (100 mL); 20 mEq/50 mL (50 mL); 40 mEq/100 mL (100 mL); 2 mEq/mL (5 mL, 10 mL, 20 mL, 30 mL, 250 mL); 20 mEq/L (1000 mL); 40 mEq/L (1000 mL); Potassium 10 mEq/100 mL and sodium chloride 0.9% (100 mL); Potassium 10 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.2% (250 mL [DSC], 500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.225% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.33% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 30 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/250 mL and sodium chloride 0.9% (250 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">K-Sol: 20 mEq/15 mL (10%) (473 mL [DSC]) [alcohol free, dye free, sugar free; contains methylparaben, propylene glycol, propylparaben, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">K-Sol: 40 mEq/15 mL (20%) (473 mL [DSC]) [alcohol free, sugar free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mEq/15 mL (10%) (15 mL, 30 mL, 473 mL, 3800 mL); 40 mEq/15 mL (20%) (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">K-Tab: 8 mEq, 10 mEq [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">K-Tab: 20 mEq</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con: 8 mEq [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con 10: 10 mEq [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con M10: 10 mEq</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con M15: 15 mEq [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con M15: 15 mEq [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con M20: 20 mEq [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con M20: 20 mEq [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mEq, 10 mEq, 20 mEq</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211789\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963621\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">750 mg potassium chloride = elemental potassium 390 mg = potassium 10 mEq = potassium 10 mmol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211806\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Potassium must be diluted prior to parenteral administration. For IV infusion; do not administer IV push. In general, the rate of administration may be dependent on patient condition and specific institution policy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Noncritical care settings: Usual range: 0.2 to 0.5 mEq/kg/hour up to 10 mEq to 20 mEq/hour have been used. Critical care settings/situations: Higher rates may be used; maximum rate: 1 mEq/kg/hour up to 40 mEq/hour; continuous cardiac monitoring recommended for rates &gt;0.5 mEq/kg/hour (Fuhrman 2017; Hamill 1991; Klaus 1989; Kliegman 2016; Kruse 1990; Lafraniere 2006; Schaber 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq/100 mL and maximum rate of administration for peripheral infusion is 10 mEq/hour (Kraft 2005). ECG monitoring is recommended for peripheral or central infusions &gt;10 mEq/hour in adults (Kraft 2005). With central line administration, higher concentrations and more rapid rates of infusion may be used; concentrations of 20 to 40 mEq/100 mL at a maximum rate of 40 mEq/hour via central line have been safely administered (Hamill 1991; Kruse 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Reynolds 2014; Zenk 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Oral: Oral dosage forms should be taken with meals (or immediately after eating) and a full glass of water or other liquid to minimize the risk of GI irritation. Prescribing information for the various oral preparations recommend that no more than 20 mEq to 40 mEq should be given as single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: MicroK: Swallow whole, do not chew. Capsules may also be opened and contents sprinkled on a spoonful of applesauce or pudding and should be swallowed immediately without chewing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder for oral solution: Klor-Con: Dissolve one packet in at least 120 mL of cold water or other beverage prior to administration. If GI irritation occurs, increase dilution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">K-Tab, Kaon-Cl, Klor-Con: Swallow tablets whole; do not crush, chew, or suck on tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Klor-Con M: Swallow tablets whole; do not crush, chew, or suck on tablet. Tablet may also be broken in half and each half swallowed separately; the whole tablet may be dissolved in ~4 ounces of water (allow ~2 minutes to dissolve, stir well and drink immediately)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211805\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypokalemia:</b> Treatment or prevention of hypokalemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211846\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kaon-Cl-10 may be confused with kaolin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">KCl may be confused with HCl</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klor-Con may be confused with Klaron</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">microK may be confused with Macrobid, Micronase </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Consider special storage requirements for intravenous potassium salts; IV potassium salts have been administered IVP in error, leading to fatal outcomes.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211796\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, abdominal distress, diarrhea, flatulence, gastrointestinal hemorrhage (oral), gastrointestinal obstruction (oral), gastrointestinal perforation (oral), nausea, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211809\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to potassium chloride or any component of the formulation; hyperkalemia, renal failure, and conditions in which potassium retention is present. In addition, solid oral dosage forms are contraindicated in patients in whom there is a structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral solution (Klor-Con): Coadministration with potassium sparring diuretics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211793\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May occur. Use with caution or avoid use in patients with predisposing conditions for hyperkalemia (eg, severe renal impairment, extensive burns or tissue injury, heart failure, acute dehydration, untreated Addison disease). Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions, including anaphylaxis and chills, may occur with parenteral administration of potassium containing solutions. Discontinue immediately if signs/symptoms of hypersensitivity/infusion reactions develop.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acid/base disorders: Use with caution in patients with acid/base alterations or acid/base correction; hyperosmolality or acidosis (or correction of alkalosis) is associated with hyperkalemia (shift of intracellular potassium to extracellular space), monitor serum potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias, atrioventricular [AV] block); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic function impairment: Use with caution in patients with cirrhosis; monitor serum potassium more frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Some products are contraindicated in patients with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral formulations: May cause GI upset and irritation (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation, and/or obstruction. Oral liquid preparations (not solid) should be used in patients with esophageal compression or delayed gastric emptying.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral administration: Use extreme caution with parenteral administration and monitor serum potassium concentrations closely. Evaluate renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Do <b>NOT</b> administer undiluted or IV push; inappropriate parenteral administration may be fatal. Always administer potassium further diluted; refer to appropriate dilution and administration rate recommendations. Pain and phlebitis may occur during parenteral infusion requiring a decrease in infusion rate or potassium concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299917\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211798\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9795&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211800\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5186460\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia) (IOM 2004). Potassium supplementation (that does not cause maternal hyperkalemia) would not be expected to cause adverse fetal events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5186463\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Potassium is present in breast milk (IOM 2004). The normal content of potassium in human milk is ~13 mEq/L. Supplementation (that does not cause maternal hyperkalemia) would not be expected to affect normal concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211812\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with plenty of fluid to decrease stomach irritation and discomfort. Some dietary sources of potassium include leafy green vegetables (eg, spinach, cabbage), tomatoes, cucumbers, zucchini, fruits (eg, apples, oranges, and bananas), root vegetables (eg, carrots, radishes), beans, and peas.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211802\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Electrolytes (including serum potassium, calcium, chloride, magnesium, phosphate, sodium), acid/base balance; renal function; cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or &gt;10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium level 2 to 4 hours after dose; monitor potassium levels daily for treatment and monthly to biannually for prophylaxis. Monitor IV infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13203026\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reference ranges may vary depending on the laboratory</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum potassium: 3.5 to 5.2 mEq/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211792\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211808\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed from upper GI tract </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Enters cells via active transport from extracellular fluid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211811\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Klor-Con Sprinkle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $90.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $95.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Micro-K Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $100.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $105.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Potassium Chloride ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $93.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $99.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Klor-Con Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (30): $322.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Potassium Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (30): $322.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (KCl in Dextrose-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq/L 5-0.45%-% (1000 mL): $3.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5-0.2%-% (1000 mL): $3.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5-0.225%-% (500 mL): $4.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5-0.33%-% (1000 mL): $2.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5-0.45%-% (1000 mL): $2.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5-0.9%-% (1000 mL): $3.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mEq/L 5-0.45%-% (1000 mL): $3.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mEq/L 5-0.45%-% (1000 mL): $3.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mEq/L 5-0.9%-% (1000 mL): $3.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Chloride in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 5% (1000 mL): $3.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mEq/L 5% (1000 mL): $3.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Chloride in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq/100 mL (100 mL): $10.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 0.45% (1000 mL): $3.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/L 0.9% (1000 mL): $3.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mEq/100 mL (100 mL): $14.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mEq/L 0.9% (1000 mL): $3.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40MEQ/250ML (250 mL): $16.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mEq/mL (10 mL): $1.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq/100 mL (100 mL): $3.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq/50 mL (50 mL): $3.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/100 mL (100 mL): $3.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq/50 mL (50 mL): $3.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mEq/100 mL (100 mL): $3.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Chloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 MEQ/15ML (10%) (15 mL): $20.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 MEQ/15ML (20%) (473 mL): $768.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (K-Tab Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $65.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $100.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (100): $99.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Klor-Con 10 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $56.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Klor-Con M10 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $59.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Klor-Con M15 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mEq (100): $99.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Klor-Con M20 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (100): $62.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Klor-Con Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $53.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Potassium Chloride Crys ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $59.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (100): $62.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Potassium Chloride ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq (100): $53.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mEq (100): $56.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mEq (100): $62.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869402\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Addi-K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM);</li>\n      <li>Alkay ER (LK);</li>\n      <li>Apo-K (HK, JO, MY, SG);</li>\n      <li>Beacon K (MY);</li>\n      <li>Budaxiu (CN);</li>\n      <li>Chloropotassuril (BE);</li>\n      <li>Clor-K-Zat (MX);</li>\n      <li>Clotassio (BR);</li>\n      <li>Co-Salt (AR);</li>\n      <li>Control K (AR);</li>\n      <li>Corpotasin (MX);</li>\n      <li>Crysta K (BD);</li>\n      <li>Di Jia (CN);</li>\n      <li>Diffu-K (FR);</li>\n      <li>Duro-K (AU);</li>\n      <li>Electro K (BD);</li>\n      <li>Enpott (TH);</li>\n      <li>Flexivial (ZA);</li>\n      <li>Gluco-K (AR);</li>\n      <li>Ionclor (BR);</li>\n      <li>K-Card (IN);</li>\n      <li>K-Chlor (PH);</li>\n      <li>K-Contin (BF, BJ, CI, ET, GH, GM, GN, KE, KR, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM);</li>\n      <li>K-Contin Continus (AE);</li>\n      <li>K-Dur (MX);</li>\n      <li>K-Retard (UY);</li>\n      <li>K-Supply (JP);</li>\n      <li>K-Tab (PK);</li>\n      <li>Kadalex (IT);</li>\n      <li>Kaion Retard (CL);</li>\n      <li>Kaldium (UA);</li>\n      <li>Kaldyum (HU, PL, VN);</li>\n      <li>Kaleorid (DK, FI, FR, IS, NO, SE, VN);</li>\n      <li>Kali-Sterop (BE);</li>\n      <li>Kaligen (PH);</li>\n      <li>Kalinor-Retard P (DE);</li>\n      <li>Kalinorm (FI);</li>\n      <li>Kaliolite (MX);</li>\n      <li>Kalipoz (PL, UA);</li>\n      <li>Kalitabs (DK);</li>\n      <li>Kalium (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZM);</li>\n      <li>Kalium-R (HN, HU);</li>\n      <li>Kalnormin (CZ);</li>\n      <li>Kalytes (PH);</li>\n      <li>Katelin (PL);</li>\n      <li>Kation (UY);</li>\n      <li>Kay-Cee-L (GB, IE, MT);</li>\n      <li>Kay-Ciel (IN);</li>\n      <li>Kaylyte (TH);</li>\n      <li>KCL Retard (BH, HN, IQ, IR, IT, LB, LY, OM, SA, SY, YE);</li>\n      <li>Kelefusin (MX);</li>\n      <li>Keylyte (IN);</li>\n      <li>KSR (HK, ID);</li>\n      <li>Lejia (CN);</li>\n      <li>Lento-Kalium (IT);</li>\n      <li>Micro-Kalium Retard (AT);</li>\n      <li>Orakit (AR);</li>\n      <li>Perennum (PY);</li>\n      <li>Plenisk-K (ZA);</li>\n      <li>Plus Kalium Retard (CH);</li>\n      <li>Potasion (ES);</li>\n      <li>Potassin (JO);</li>\n      <li>Potassride (TH);</li>\n      <li>Potazek (PL);</li>\n      <li>Potklor (IN);</li>\n      <li>Rekawan (DE);</li>\n      <li>Sando-K (GB);</li>\n      <li>Sandoz K (ZA);</li>\n      <li>Slow-K (AR, AT, AU, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CL, EG, ET, GB, GH, GM, GN, GY, HK, IE, IL, IQ, IR, JM, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, OM, PR, QA, SA, SC, SD, SG, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Slow-K MR (CY, TR);</li>\n      <li>Span-K (AU, HK, MY, NZ, PH, SG);</li>\n      <li>Susta-K (ZW);</li>\n      <li>Sylvite (PH);</li>\n      <li>Tascit (LK);</li>\n      <li>Xian Jia (CN);</li>\n      <li>Xin Jian Ju (CN);</li>\n      <li>Zerosodio (BR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alfonzo AV, Isles C, Geddes C, et al, &ldquo;Potassium Disorders - Clinical Spectrum and Emergency Management,&rdquo; <i>Resuscitation</i>, 2006, 70(1):10-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/16600469/pubmed\" target=\"_blank\" id=\"16600469\">16600469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2002, 26(1 Suppl):22-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo; <i>JPEN J Parenter Enteral Nutr</i>, 2002, 26(1 Suppl):25-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy DF. Chapter 36. Disorders of Potassium and Magnesium Homeostasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. <i>Pharmacotherapy: A Pathophysiologic Approach, 9e</i>. New York, NY: McGraw-Hill; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flurie RW, Brophy DF, et al. Pharmacotherapy:A Pathophysiologic Approach, 10th ed. Chapter 51: Disorders of Potassium and Magnesium Homeostasis. New York, NY: McGraw-Hill Education. Available at http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&amp;sectionid=134127639. 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hadaway L. Infiltration and extravasation [published correction appears in <i>Am J Nurs</i>. 2007;107(10):15]. <i>Am J Nurs</i>. 2007;107(8):64-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/17667395/pubmed\" target=\"_blank\" id=\"17667395\">17667395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamill RJ, Robinson LM, Wexler HR, Moote C. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. <i>Crit Care Med</i>. 1991;19(5):694-699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/2026032/pubmed\" target=\"_blank\" id=\"2026032\">2026032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>, Washington, DC: National Academy Press, 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khilnani P, &ldquo;Electrolyte Abnormalities in Critically Ill Children,&rdquo; <i>Crit Care Med</i>, 1992, 20(2):241-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/1737458/pubmed\" target=\"_blank\" id=\"1737458\">1737458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: Pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/10318297/pubmed\" target=\"_blank\" id=\"10318297\">10318297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klor-con (potassium chloride) [prescribing information]. Princeton, NJ: Sandoz Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klor-con M (potassium chloride) [prescribing information]. Princeton, NJ: Sandoz Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knudson JD, Lowry AW, Price JF, Moffett BS. Response to intravenous potassium chloride supplementation in pediatric cardiac intensive care patients. <i>Pediatr Cardiol</i>. 2013;34(4):887-892.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/23124387/pubmed\" target=\"_blank\" id=\"23124387\">23124387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005, 62(16):1663-1682.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/16085929/pubmed\" target=\"_blank\" id=\"16085929\">16085929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. <i>Arch Intern Med</i>. 1990;150(3):613-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/2310280/pubmed\" target=\"_blank\" id=\"2310280\">2310280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K-Tab (potassium chloride) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klor-Con Powder (potassium chloride) [prescribing information]. Upsher-Smith Labs; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals,&rdquo; available at http://www.jointcommission.org/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffett BS, McDade E, Rossano JW, Dickerson HA, Nelson DP. Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change. <i>Pediatr Crit Care Med</i>. 2011;12(5):552-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/21297518 /pubmed\" target=\"_blank\" id=\"21297518 \">21297518 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potassium Chloride (flexible plastic container) [package insert]. Deerfield, IL: Baxter Healthcare Corporation; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potassium chloride [prescribing information]. Irvine, CA: B. Braun Medical Inc; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss-Guillet EM, Takala J, and Jakob SM, &ldquo;Diagnosis and Management of Electrolyte Emergencies,&rdquo; <i>Best Pract Res Clin Endocrinol Metab</i>, 2003, 17(4):623-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-chloride-drug-information/abstract-text/14687593/pubmed\" target=\"_blank\" id=\"14687593\">14687593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9795 Version 253.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211820\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F211821\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211838\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211823\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F211833\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211824\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448467\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448468\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211804\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211789\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963621\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211806\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211805\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F211846\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211796\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211809\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211793\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299917\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211798\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211800\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5186460\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5186463\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F211812\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F211802\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F13203026\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211792\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211808\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F211811\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869402\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9795|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-chloride-patient-drug-information\" class=\"drug drug_patient\">Potassium chloride: Patient drug information</a></li><li><a href=\"topic.htm?path=potassium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">Potassium chloride: Pediatric drug information</a></li></ul></div></div>","javascript":null}